Ekso Bionics Receives General Services Administration Listing
August 15 2018 - 9:00AM
Facilitates potential future purchases by the
U.S. Department of Veterans Affairs
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), an industry leader in
exoskeleton technology for medical and industrial use, today
announced that U.S. government’s General Services Administration
(GSA) has added the company to its list of contracted Federal
Business Opportunities (FBO).
“We are pleased that Ekso Bionics has been added
to the GSA’s listing of Federal Business Opportunities,” said Jack
Peurach, President and Chief Executive Officer of Ekso Bionics. “We
believe that this listing will facilitate potential future
opportunities to make EksoGT part of the standard of care for
rehabilitation of stroke and spinal cord injury in patients treated
at the VA. We believe that EksoGT would offer a compelling value
proposition to the VA and enhance the Department’s ability to
provide high-quality, cost-effective rehabilitation services for
patients with stroke and spinal cord injury.”
Established in 1949 with a mission to deliver
value and savings in real estate, acquisition, technology, and
other mission-support services across Government, the GSA is tasked
with administering supplies and providing workplaces for federal
employees. Toward this end, the GSA provides centralized
procurement for the federal government, offering billions of
dollars worth of products, services, and facilities that federal
agencies need to serve the public.
About Ekso Bionics®
Ekso Bionics® is a leading developer of exoskeleton solutions
that amplify human potential by supporting or enhancing strength,
endurance and mobility across medical and industrial applications.
Founded in 2005, the company continues to build upon its
unparalleled expertise to design some of the most cutting-edge,
innovative wearable robots available on the market. Ekso Bionics is
the only exoskeleton company to offer technologies that range from
helping those with paralysis to stand up and walk, to enhancing
human capabilities on job sites across the globe. The company is
headquartered in the Bay Area and is listed on the Nasdaq Capital
Market under the symbol EKSO. For more information, visit:
www.eksobionics.com.
Forward-Looking StatementsAny
statements contained in this press release that do not describe
historical facts may constitute forward-looking statements.
Forward-looking statements may include, without limitation,
statements regarding (i) the plans and objectives of management for
future operations, including plans or objectives relating to the
design, development and commercialization of human exoskeletons,
(ii) estimates or projection of financial results, financial
condition, operating results, capital expenditures, capital
structure, continued momentum in commercialization efforts,
expansion of product footprint or other financial or operational
items, (iii) the Company's future financial performance, and (iv)
the assumptions underlying or relating to any statement described
in points (i), (ii) or (iii) above. Such forward-looking statements
are not meant to predict or guarantee actual results, performance,
events or circumstances and may not be realized because they are
based upon the Company's current projections, plans, objectives,
beliefs, expectations, estimates and assumptions and are subject to
a number of risks and uncertainties and other influences, many of
which the Company has no control over. Actual results and the
timing of certain events and circumstances may differ materially
from those described by the forward-looking statements as a result
of these risks and uncertainties. Factors that may influence or
contribute to the inaccuracy of the forward-looking statements or
cause actual results to differ materially from expected or desired
results may include, without limitation, changes resulting from the
Company’s finalization of its financial statements for and as of
the three and six months ended June 30, 2018, information or new
changes in facts or circumstances that may occur prior to the
filing of the Company’s Quarterly Report on Form 10-Q that are
required to be included therein, the Company's inability to obtain
adequate financing to fund the Company's operations and necessary
to develop or enhance our technology, the significant length of
time and resources associated with the development of the Company's
products, the Company's failure to achieve broad market acceptance
of the Company's products, the failure of the Company’s sales and
marketing organization or partners to market the Company’s products
effectively, adverse results in future clinical studies of the
Company's medical device products, the failure to obtain or
maintain patent protection for the Company's technology, failure to
obtain or maintain regulatory approval to market the Company's
medical devices, lack of product diversification, existing or
increased competition, and the Company's failure to implement the
Company's business plans or strategies. These and other factors are
identified and described in more detail in the Company's filings
with the SEC. To learn more about Ekso Bionics please visit us at
www.eksobionics.com or refer to our Twitter page at @EksoBionics.
The Company does not undertake to update these forward-looking
statements.
Media Contact:Chantal
Beaudry212-867-1762cbeaudry@lazarpartners.com
Investor Contact: David
Carey212-867-1768investors@eksobionics.com
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Sep 2023 to Sep 2024